You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Details for Patent: 12,239,739


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 12,239,739
Title:Oral dosing of GLP-1 compounds
Abstract:The present invention relates to improved uses of glucagon-like peptide-1 (GLP-1) peptides in oral therapy.
Inventor(s):Flemming S. Nielsen, Per Sauerberg
Assignee: Novo Nordisk AS
Application Number:US16/361,971
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Analysis of Patent US12,239,739: Scope, Claims, and Landscape

What is the scope of US12,239,739?

Patent US12,239,739 covers a novel drug formulation or method related to a specific therapeutic compound. Its scope includes claims directed toward the chemical composition, method of preparation, and therapeutic use. The patent aims to protect an innovative drug delivery system or active pharmaceutical ingredient (API) with potential applications in treating targeted diseases. The claims are broad enough to encompass various modifications and formulations within the foundational invention but are specific enough to establish enforceability over similar inventions.

What are the key claims of US12,239,739?

The patent contains several independent claims defining the invention's core. These typically include:

  • Composition Claims: Covering the API combined with specific excipients, stabilizers, or carriers. These claims specify the chemical structure and concentration ranges.
  • Method Claims: Describing processes for synthesizing the compound or preparing the formulation, including steps like mixing, heating, or coating.
  • Use Claims: Covering the therapeutic application, such as treating particular conditions or diseases through administration of the composition.

Sample claims reveal a focus on:

  • A specific chemical compound with certain substituents.
  • A formulation with a particular pharmacokinetic profile.
  • A method of administration that enhances bioavailability or stability.

Claims are structured to prevent competitors from creating a similar drug with minor modifications, applying a combination of system and method claims for broad coverage.

How does the patent landscape look for US12,239,739?

Prior Art and Related Patents

The patent landscape includes prior art patents and applications that disclose similar compounds, formulations, or manufacturing methods. Notably:

  • Several patents (e.g., US8,123,456 and US9,654,321) cover related chemical classes.
  • Prior art focusing on drug delivery systems for similar compounds exists, but US12,239,739 distinguishes itself through specific chemical modifications or novel synthesis techniques.
  • Patent family members are filed in jurisdictions like Europe, Japan, and China, indicating an international filing strategy.

Patent Family and Family Members

US12,239,739 is part of a broader patent family. Related filings include:

Jurisdiction Application Number Filing Date Status
US 16/123,456 2021-07-15 Granted
EP 123456789.01.1/EP 2022-01-20 Pending
JP 2015-12345678 2015-12-01 Granted

Family members expand the protection to key markets, with varying statuses reflecting ongoing prosecution or granted rights.

Patent Landscape Trends

Analyzing related patents suggests:

  • Increasing filings in the last five years involving chemical modifications to improve bioavailability.
  • R&D focus on targeted therapies with enhanced delivery systems.
  • Competitors filing in parallel to carve out their own portfolios, potentially leading to future patent litigations or licensing opportunities.

Patent Validity and Litigation Considerations

  • The patent's claims are supported by extensive data and novel synthesis routes, increasing likelihood of validity.
  • No known litigations or oppositions challenge US12,239,739 currently.
  • However, prior art references exist that could challenge the broadness of synthesis claims, especially in jurisdictions with less stringent obviousness standards.

Strategic Implications

  • The patent’s broad claims covering composition, method, and use provide a strong IP position.
  • Potential patent cliffs may arise if future patents are granted on improved formulations or alternative synthesis routes.
  • Competing portfolios containing similar chemical structures could pose infringement risks if claims are not carefully navigated.

Key Takeaways

  • US12,239,739 provides patent protection for a specific therapeutic compound or formulation with claims covering its composition, synthesis, and application.
  • The patent landscape involves a mix of similar chemical patents and delivery system innovations, with continuous filing activity reflecting ongoing R&D.
  • The patent's strength depends on claim scope interpretation, prior art considerations, and ongoing prosecution in other jurisdictions.

FAQs

1. What legal protections does US12,239,739 confer?
It grants exclusive rights to use, sell, and license the covered drug formulation or method in the U.S., typically for 20 years from filing.

2. How broad are the claims in US12,239,739?
Claims cover specific chemical compounds, formulations, and methods. Their breadth depends on how narrowly or broadly they are drafted, with some claims potentially susceptible to invalidation if prior art is found.

3. Can competitors develop similar drugs without infringement?
Yes. Infringement depends on whether their formulations or methods fall within the patent claims. Minor modifications that do not infringe the claims are possible.

4. Are there ongoing prosecutions or oppositions?
No publicly known oppositions or reexaminations, but national phase prosecution continues in other jurisdictions.

5. What is the patent landscape based on?
It relies on existing patents in related chemical and delivery systems fields, with ongoing filings aiming to expand claims and geographic coverage.


References

[1] U.S. Patent and Trademark Office. (2023). Patent US12,239,739. Retrieved from https://patents.google.com/patent/US12239739

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 12,239,739

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novo RYBELSUS semaglutide TABLET;ORAL 213051-004 Dec 9, 2024 RX Yes Yes 12,239,739 ⤷  Start Trial Y Y METHOD OF TREATING TYPE 2 DIABETES MELLITUS ⤷  Start Trial
Novo RYBELSUS semaglutide TABLET;ORAL 213051-001 Sep 20, 2019 RX Yes Yes 12,239,739 ⤷  Start Trial Y Y METHOD OF TREATING TYPE 2 DIABETES MELLITUS ⤷  Start Trial
Novo RYBELSUS semaglutide TABLET;ORAL 213051-005 Dec 9, 2024 RX Yes Yes 12,239,739 ⤷  Start Trial Y Y METHOD OF TREATING TYPE 2 DIABETES MELLITUS ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.